市場調查報告書

骨質疏鬆症治療藥的全球市場 - 產業洞察,趨勢,預測,市場機會分析 2018年∼2026年

Osteoporosis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

出版商 Coherent Market Insights 商品編碼 785780
出版日期 內容資訊 英文 165 Pages
商品交期: 2-3個工作天內
價格
骨質疏鬆症治療藥的全球市場 - 產業洞察,趨勢,預測,市場機會分析 2018年∼2026年 Osteoporosis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
出版日期: 2018年08月07日內容資訊: 英文 165 Pages
簡介

骨質疏鬆症新藥的認證和上市,預測將大幅推進骨質疏鬆症治療藥市場的成長。

本報告提供骨質疏鬆症治療藥市場調查,提供市場概要,醫藥品類型·給藥途徑·通路·各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的及其前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場範圍

  • 市場概要
  • 報告的說明
  • 市場定義和範圍
  • 摘要整理
  • 市場片段:醫藥品類別
  • 市場片段:各給藥途徑
  • 市場片段:各銷售管道
  • 市場片段:各地區
  • 連貫機遇地圖(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
  • 成長要素
  • 阻礙因素
  • 市場機會
  • PEST分析
  • 開發平台分析
  • 產品核可
  • 產品銷售
  • 聯盟·收購
  • 波特的五力分析

第4章 全球骨質疏鬆症治療藥市場:醫藥品類別

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 雙膦酸鹽
  • 抑鈣素
  • 荷爾蒙療法
  • 選擇性雌激素受體調節(SERM)
  • 副甲狀腺素相關蛋白質(PTHrP)類似物
  • Rank Ligand(RANKL)抑製劑

第5章 全球骨質疏鬆症治療藥市場:各給藥途徑

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 口服給藥
  • 靜脈注射
  • 其他

第6章 全球骨質疏鬆症治療藥市場:各銷售管道

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 醫院
  • 線上藥局
  • 零售藥局

第7章 全球骨質疏鬆症治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭環境

  • 熱圖分析
  • 企業簡介
  • Teva Pharmaceutical Industries Ltd.
  • 第一三共
  • Amgen Inc.
  • Dr Reddy's Laboratories
  • Mylan Inc.
  • Pfenex Inc.
  • Eli Lilly and Company
  • 旭化成
  • F.Hoffmann La Roche
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co AG
  • GlaxoSmithKline Plc.
  • Allergan plc.
  • Pfizer Inc.

第9章 章節

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Osteoporosis is a bone related disease that weakens bones and increase the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis – particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. The prevalence of osteoporosis is high among the adult population. For instance, according to a report by National Osteoporosis Foundation in 2016, around 54 million adult in the U.S were suffering from osteoporosis or have low bone density.

Market Dynamics

Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over forecast period. For instance, in 2013, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for its drug— DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets—for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Furthermore, osteoporosis commonly affects older adults and increasing geriatric population is expected to lead to high demand for osteoporosis treatment drugs. For instance, according to a report by United Nations Population Fund, people aged 60 years and above accounted for 12.3% of the global population in 2015 and this is expected to reach 22% by 2050 that accounts for 2 billion people.

Key features of the study:

This report provides in-depth analysis of the osteoporosis treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

It profiles leading players in the global osteoporosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

Key companies covered as a part of this study include, EffRx Pharmaceuticals SA, Daiichi Sankyo Company, Limited, Amgen Inc., Dr Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co AG, GlaxoSmithKline Plc., Allergan plc., and Pfizer Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technological up-gradation, market expansion, and marketing tactics

The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the osteoporosis treatment market

Detailed Segmentation:

  • Global Osteoporosis Treatment Market, by Drug Type :
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • Global Osteoporosis Treatment Market, by Route of Administration:
  • Oral
  • Injectable
  • Others
  • Global Osteoporosis Treatment Market, by Distribution Channel:
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • Global Osteoporosis Treatment Market, by Geography:
  • North America
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Daiichi Sankyo Company Limited.
  • Amgen Inc.
  • Dr Reddy\'s Laboratories
  • Mylan Inc.
  • Pfenex Inc.
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • F.Hoffmann La Roche
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co AG
  • GlaxoSmithKline Plc.
  • Allergan plc.
  • Pfizer Inc.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • PEST Analysis
    • Pipeline Analysis
    • Product Approval
    • Product Launch
    • Collaboration-Acquisition
    • Porter's Five Forces Analysis

4. Global Osteoporosis Treatment Market, By Drug Type, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Bisphosphonates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Segment Trends
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Selective Estrogen Receptor Modulators (SERMs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Rank Ligand (RANKL) Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

5. Global Osteoporosis Treatment Market, By Route of Administration, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

6. Global Osteoporosis Treatment Market, By Distribution Channel, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

7. Global Osteoporosis Treatment Market, By Region, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
    • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Daiichi Sankyo Company Limited.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Dr Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfenex Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Asahi Kasei Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F.Hoffmann La Roche
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • EffRx Pharmaceuticals SA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact